Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
(NASDAQ:ADIL) GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve...
What upcoming catalysts (e.g., clinical trial updates, partnership announcements, or financing events) could help the company regain compliance and support a sustainable price rebound?
How will the compliance deadline and potential delisting risk affect the stock’s liquidity, short‑interest, and price volatility?
What is the probability that Adial Pharmaceuticals will recover a bid price above $1.00 within the 180‑day extension timeframe?
8 days ago